Definium Therapeutics Inc (DFTX) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Clinical development updates

• Advancing MM120 (LSD) for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with phase III trials launching in late 2024 for GAD and early 2025 for MDD.

• MM120 demonstrated multi-month durable effects after a single dose in phase IIb, with about 50% remission at 12 weeks and a significant effect size over standard of care.

• MM402 (R-MDMA) is in phase I for autism spectrum disorder, aiming for early phase II efficacy studies.

• Three phase III catalysts are expected across 2026, with ongoing regulatory and clinical milestones anticipated.

• Trial design includes up to four open-label doses and a primary endpoint at 12 weeks, with adaptive sample size re-estimation to maintain statistical power.

Regulatory and trial design considerations

• Proactive engagement with FDA and a drug-only approach (no psychotherapeutic intervention) to avoid complexities seen in other programs.

• Addressing functional unblinding through independent raters and third-party verification to ensure robust trial blinding and patient selection.

• Monitoring intervals for dosing sessions reduced from 12 to 8 hours, with data-driven criteria for patient discharge, aiming for further streamlining.

Market opportunity and commercial strategy

• GAD and MDD have high comorbidity and overlapping symptoms, offering potential for a broad treatment label and greater patient access.

• Durability of effect is a key differentiator, with potential for episodic treatment rather than chronic dosing, similar to an antibiotic model.

• Pricing strategy considers annual treatment costs, benchmarking against products like Spravato, and aims for attractive economics if infrequent dosing is effective.

• Commercial challenges include evolving infrastructure, need for more treatment centers, and overcoming social and medical perceptions of LSD.